All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Novel Nephrology Drugs in Discovery

All Data

Filters

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

Product Type

Companies

Novome Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: DCVC Bio

Deal Size: $33.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2020

Details:

The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.